BeiGene breaks ground on new manufacturing and clinical R&D center in Hopewell

Company plans to develop 42-acre site at Princeton West Innovation Park; create hundreds of jobs

Gov. Phil Murphy and Mayor Courtney Peters-Manning, along with John V. Oyler, co-founder, chairman and CEO of BeiGene, are celebrating a Friday groundbreaking of a new U.S. manufacturing and clinical research & development center at the Princeton West Innovation Park in Hopewell.

The facility is expected to include up to approximately 400,000 square feet of dedicated commercial-stage biologic pharmaceutical manufacturing, including up to 16,000 liters of biologics capacity, along with clinical R&D and office space. Construction of the initial phase is expected to be completed in late 2023 or in 2024. In addition, the property has more than 1 million square feet of developable real estate for potential future expansion.

The project has plans to create hundreds of jobs from the region’s deep talent pool to support BeiGene’s continued growth in the U.S. and commitment to developing and commercializing innovative and affordable cancer medicines.

In November 2021, BeiGene acquired the Hopewell property from Lincoln Equities Group and retained DPR Construction as its construction management firm and IPS-Integrated Project Services LLC as its architectural and engineering firm.

“Our planned flagship U.S. R&D and manufacturing center supports our commitment to fight for life for people living with cancer around the world, through state-of-the-art commercial-stage biologic pharmaceutical manufacturing, late-stage research and clinical development capabilities,” Oyler said. “The Princeton-Hopewell area is an excellent location for BeiGene and the thriving life science community, with a deep talent pool, as we continue to advance our pipeline of innovative cancer medicines and work to diversify our global supply chain.”

“BeiGene’s plans for hundreds of new jobs in New Jersey speak to our efforts to grow our state’s business-friendly environment and to our commitment to fostering innovation,” Murphy said. “We are proud to welcome BeiGene to the Princeton area and look forward to the company manufacturing innovative cancer medicines in its new state-of-the-art facility.”

“As a leader with a long history in New Jersey’s biotech industry, Hopewell Township welcomes BeiGene to our community,” Peters-Manning said. “We are pleased that BeiGene will bring their state-of-the-art technologies, manufacturing and R&D center to Hopewell, whose products will help countless people all over the world. We look forward to continuing to work with BeiGene and are excited about what will be produced here in Hopewell.”